US equities |
NVDA $175.28 ▼-6.09% AMD $497.78 ▲+10.85% MU $733.18 ▲+6.26% SPCX $141.92 ▲+5.70% AMZN $267.91 ▲+3.32% SNDK $889.32 ▲+6.50% TSLA $377.69 ▲+5.43% META $639.29 ▲+4.78%
FinancialContent

Articles published by Innovation Pharmaceuticals Inc.

News headline image
Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Provides Brilacidin Program Update
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin's Potential Inclusion in Government-Sponsored COVID-19 Trials
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19
From Innovation Pharmaceuticals Inc.
Via AccessWire
Topics Death
Tickers IPIX
News headline image
Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals' COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
News headline image
Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin's Broad-Spectrum Antiviral Properties
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX